Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRC-063 vs Lisdexamfetamine Driving Performance in Adult ADHD
NCT02555150Phase 3Completed
- Sponsor
- Rhodes Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD), sponsored by Rhodes Pharmaceuticals. Started Sep 2015; status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02555150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555150.